WallStSmart

Morgan Stanley (MS)vsStryker Corporation (SYK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Morgan Stanley generates 190% more annual revenue ($73.17B vs $25.27B). MS leads profitability with a 24.7% profit margin vs 13.2%. SYK appears more attractively valued with a PEG of 1.39. MS earns a higher WallStSmart Score of 73/100 (B).

MS

Strong Buy

73

out of 100

Grade: B

Growth: 9.3Profit: 7.5Value: 5.7Quality: 4.8
Piotroski: 3/9

SYK

Buy

59

out of 100

Grade: C

Growth: 6.0Profit: 7.0Value: 4.7Quality: 6.0
Piotroski: 3/9Altman Z: 2.18
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for MS.

SYKOvervalued (-7.6%)

Margin of Safety

-7.6%

Fair Value

$265.38

Current Price

$285.47

$20.09 premium

UndervaluedFair: $265.38Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MS6 strengths · Avg: 8.8/10
Market CapQuality
$299.95B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
40.6%10/10

Strong operational efficiency at 40.6%

Profit MarginProfitability
24.7%9/10

Keeps 25 of every $100 in revenue as profit

P/E RatioValuation
17.2x8/10

Attractively priced relative to earnings

Price/BookValuation
3.0x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
16.3%8/10

16.3% revenue growth

SYK1 strengths · Avg: 9.0/10
Market CapQuality
$112.69B9/10

Large-cap with strong market position

Areas to Watch

MS3 concerns · Avg: 3.0/10
PEG RatioValuation
2.334/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Free Cash FlowQuality
$-7.85B2/10

Negative free cash flow — burning cash

SYK3 concerns · Avg: 3.7/10
P/E RatioValuation
34.0x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
2.6%4/10

2.6% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : MS

The strongest argument for MS centers on Market Cap, Operating Margin, Profit Margin. Profitability is solid with margins at 24.7% and operating margin at 40.6%. Revenue growth of 16.3% demonstrates continued momentum.

Bull Case : SYK

The strongest argument for SYK centers on Market Cap. PEG of 1.39 suggests the stock is reasonably priced for its growth.

Bear Case : MS

The primary concerns for MS are PEG Ratio, Piotroski F-Score, Free Cash Flow.

Bear Case : SYK

The primary concerns for SYK are P/E Ratio, Revenue Growth, Piotroski F-Score.

Key Dynamics to Monitor

MS profiles as a growth stock while SYK is a value play — different risk/reward profiles.

MS carries more volatility with a beta of 1.21 — expect wider price swings.

MS is growing revenue faster at 16.3% — sustainability is the question.

SYK generates stronger free cash flow (415M), providing more financial flexibility.

Bottom Line

MS scores higher overall (73/100 vs 59/100), backed by strong 24.7% margins and 16.3% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Morgan Stanley

FINANCIAL SERVICES · CAPITAL MARKETS · USA

Morgan Stanley is an American multinational investment bank and financial services company headquartered at 1585 Broadway in the Morgan Stanley Building, Midtown Manhattan, New York City.

Stryker Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.

Visit Website →

Want to dig deeper into these stocks?